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In the absence of an effective vaccine, educational or
interventional strategies that decrease sexual transmission of
HIV hold the greatest promise for slowing infection rates.
Although a safe and effective microbicide could greatly
help in this regard, progress in this area has been disappointing
with microbicide development often failing to take into
account advances in our understanding of how HIV is
transmitted and infects cells. In this issue, Hu et al. demon-
strate that HIV infection of human cervical tissue ex vivo
can be prevented not only by using antibodies that target
the virus but by a cocktail of compounds that target the cell
surface receptors to which the virus binds, thus providing a
basis for the design of microbicides that prevent virus infec-
tion in a highly specific manner (1).
Potential microbicides for HIV can be placed into one of
three categories: compounds that inhibit virus infection
nonspecifically, compounds that specifically target the virus,
and compounds that target the cell surface receptors to
which the virus binds. Most microbicide candidates tested
to date fall squarely into the first category and illustrate the
pitfalls of using agents that do not discriminate between
pathogen and host. The first candidate microbicide for HIV
to reach phase III clinical trials was the spermicidal detergent
nonoxynol-9. Although the compound inactivates HIV in
vitro by disrupting the outer viral membrane, it failed to
prevent sexual transmission of the virus in vivo (2). In fact,
women who used nonoxyl-9 containing gels had a higher
rate of infection by HIV, most likely because the detergent
disrupted the membranes of the epithelial cells in the genital
tract which otherwise serve as an important barrier to virus
infection. The failure of nonoxynol-9 has increased interest
in agents that more specifically target HIV.
That HIV transmission can be prevented has been shown
most clearly through the use of neutralizing antibodies.
Passive administration of neutralizing antibodies can confer
sterilizing immunity to macaques who are vaginally challenged
with virus, provided that the antibodies are present within
several hours of virus application (3–5). Likewise, a vagi-
nally applied neutralizing antibody prevented infection of
macaques (6). Although promising, the greatest drawbacks
to the use of monoclonal antibodies is their cost and the
structural variability of the viral Env protein to which they
bind (7). Only a handful of broadly cross-reactive, neutral-
izing antibodies have been developed over the past 20 yr,
and none of these recognize all virus strains. Even when
used in combination, it is not difficult to identify virus
strains that are neutralized only at very high concentrations
of antibody or that escape neutralization altogether. Still,
these results demonstrate that specific antiviral agents can
prevent transmission of virus across the genital mucosa.
Recently, an impressive array of small molecule inhibitors
that prevent HIV entry into cells have been developed,
with many in clinical trials and one having been licensed in
2003 (8). Since viral attachment to and entry into host cells
is the first step in establishing an infection, this process is a
particularly attractive target for microbicides. Because attach-
ment and entry involve interactions between the virus and
host cells, it is important to use model systems that recapit-
ulate the cellular environment in which infection is thought
to occur as closely as possible. A major strength of the Hu
et al. study is the use of human cervical tissue explants to
elucidate the pathways by which HIV can establish an in-
fection in genital mucosal tissue (1). Their work suggests
two important principles that should guide the formulation
of new microbicides. First, there are multiple ways by
which HIV can infect target cells in the genital mucosa
(Fig. 1). Thus, a successful host-targeted microbicide for-
mulation will have to block all the potential pathways of
HIV entry. Second, even if all host receptors for viral entry
are blocked, HIV may be capable of evading these inhibitors
by hitching a ride on dendritic cells (DCs). This may allow
HIV to remain in an infectious state long enough to reach
areas where microbicides do not penetrate (Fig. 1). As a result,
targeting the molecules on the DC surface to which the virus
binds may also be necessary for a microbicide to be as effective
as possible.
 
Cell Surface Molecules Involved in Virus Infection.
 
At the min-
imum, HIV must interact with two receptors, CD4 and a
coreceptor, to activate the membrane fusion potential of
the viral Env protein (8). All HIV strains identified to date
use the chemokine receptors CCR5 or CXCR4 as core-
ceptors to infect cells. Since viruses that use CCR5 cause
the vast majority of new infections, this coreceptor is of
particular interest (9, 10). However, utilization of alterna-
tive coreceptors for virus infection, such as CCR2 and
CCR3, can sometimes be demonstrated in vitro. Hu et
al. confirmed that both CCR5 and CXCR4-tropic HIV
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strains (R5 and X4, respectively) are capable of replication
in cervical tissue stimulated with the T cell mitogen phyto-
hemagluttinin (1). As expected, a small molecule inhibitor
that targets CCR5 prevented infection by R5 virus strains
but failed to neutralize infection by viruses that are capable
of using CXCR4, whereas a CXCR4 inhibitor did the op-
posite. Importantly, although one of the HIV strains tested
by the authors was capable of using the alternative corecep-
tors CCR3, CCR8, and CXCR6 in vitro, simultaneous
blockade of CCR5 and CXCR4 by small molecule inhibi-
tors was sufficient to prevent infection of the explants, sug-
gesting that these alternative coreceptors were not relevant
in the setting of this primary tissue. Therefore, a microbi-
cide formulation directed against chemokine receptors will
probably need to target only CCR5 and CXCR4 in order
to block localized mucosal infection by HIV.
 
DCs: Another Viral Doorway.
 
Hu et al. also investigated
the relative importance of host proteins involved in the cap-
ture of HIV by host DC (1). Cocultures of human DCs and
T cells support higher levels of HIV replication than when
T cells are cultured alone (11). This effect is partly explained
by the ability of DCs to efficiently capture HIV through
“attachment factors” such as DC-SIGN, a calcium depen-
dent (C-type) lectin that binds high mannose oligosaccha-
ride groups on the HIV Env glycoprotein (12). Although
attachment of HIV to DC-SIGN alone does not cause vi-
rus–cell fusion, captured HIV is efficiently routed to sites of
contact between DCs and T cells in vitro. CD4, CCR5,
and CXCR4 on the T cell are also routed to this site of
contact, and this is believed to facilitate viral entry into the
T cell (13). To see if this capture and transfer mechanism
might play a role in direct infection of cervical explants, the
authors used a saturating concentration of the yeast cell wall
component mannan, which blocks HIV binding to DC-
SIGN and at least some other C-type lectins. Treatment
with mannan or antibodies to DC-SIGN failed to affect the
levels of infection, even when viral input was varied across a
100-fold range. This suggests that interactions between
HIV, DC-SIGN, and other C-type lectins that are compe-
tent to bind mannan did not contribute significantly to di-
rect infection of local T cells and macrophages.
Although DCs may initiate HIV infection of T cells in
vitro, they may play an additional role in vivo: dissemina-
tion of virus from local sites of infection to proximally lo-
cated lymphoid organs. In rhesus macaques, DCs bearing
simian immunodeficiency virus can be seen in draining
lymph tissue as early as 30 min after vaginal simian immun-
odeficiency virus challenge (14). To model the fate of HIV
carried to lymph nodes by DCs, Hu et al. stimulated their
infected explants with chemokines to induce DC migration
and harvested the emigrating cells. When T cells were
added to this emigrating cell population, strong HIV repli-
cation was seen, indicating that the emigrating cells carried
HIV in an infectious state. Since the emigrating cells were
Figure 1. Mucosal transmission of HIV.
Mechanisms by which HIV may traverse
the epithelium include tears in the epithe-
lium, transcytosis, and interactions with
Langerhans cells. In the submucosal space,
HIV may infect local T cells or mac-
rophages that express CD4 and either
CXCR4 or CCR5. Virus entry can be
blocked by agents that prevent binding of
the viral Env protein to either CD4 or the
viral coreceptor. However, HIV may still be
able to establish an infection by binding to
CD4, DC-SIGN, or other attachment mol-
ecules on the surface of DCs. HIV may be
internalized by the DCs, and upon DC mat-
uration (which may be triggered by HIV)
and emigration from the submucosa via the
lymphatics to regional lymph nodes, be
delivered to an area rich in T cells but defi-
cient in topically applied entry inhibitors.
Thus, blocking direction infection of cells
in the submucosa and interactions with DCs
may be required to efficiently inhibit sexual
transmission of HIV. 
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composed of both T cells and DCs, the authors separated
the two populations with magnetic beads and found that
the majority of the infectious HIV was carried by the DC
fraction. If the cervical explants were preincubated with
mannan or antibodies against CD4 or DC-SIGN before
addition of virus, the amount of HIV carried by the DCs
was significantly reduced. Importantly, the DCs carried
HIV even when localized infection in the cervical explants
was largely blocked by coreceptor inhibitors or antibody to
CD4. This is an important result because it indicates that
simply blocking host molecules required for localized in-
fection in the cervix may not be enough to prevent sexual
transmission of HIV. In fact, a recent study published in
this journal showed that a CCR5 inhibitor, when used
alone, provided full protection to only 2 of 11 macaques
that were vaginally challenged with virus (15).
 
Conflicting Results on the Role of DCs.
 
Superficially, it might
seem that the results of Hu et al. (1) are somewhat at odds
with two recent studies that examined the fate of HIV
bound by DCs (16, 17). Findings by Turville et al. question
whether DCs really do retain HIV for long periods (16)
and argue that direct infection of DCs is responsible for
long-term preservation of HIV infectivity. However, this
study used DCs that were grown in vitro from blood pro-
genitor cells, whereas the DCs studied by Hu et al. are au-
thentic DCs taken from a tissue that is highly relevant for
HIV transmission (1), and may vary in important ways
from blood-derived DCs. More importantly, the findings
of Turville et al. applied mainly to nonactivated (immature)
DCs (16), whereas the emigrating DCs studied by Hu et al.
expressed CD83 (1), indicating that they were of a mature
phenotype. When Turville et al. studied mature DCs, they
found that there was some long term preservation of HIV
in mature DCs in the absence of infection (16). In the sec-
ond study that questions the ability of DCs to capture and
retain HIV, skin explants were used to investigate a special-
ized subset of immature DCs known as Langerhans cells
(17). These cells could be infected directly by R5 but not
X4 HIV strains. Langerhans cells that emigrated from the
skin explants did not carry HIV if direct infection was
blocked, and preincubation of the explants with mannan
had no effect on the amount of infection observed or the
ability of the cells to transmit the HIV to T cells. Again, the
difference between this study and that of Hu et al. is in
the type of DC examined. The DCs in the explants used by
Hu et al. likely included both DC-SIGN–negative Langer-
hans DCs from the cervical epithelium and DC-SIGN–
positive interstitial DCs from the lamina propria. A C-type
lectin-dependent pathway of HIV transmission has been
established only for the latter DC subset, as most studies
have used in in vitro monocyte-derived DCs, which most
closely resemble interstitial DCs. In the setting of an intact
epithelial barrier, only Langerhans cells would be expected
to interact with HIV, whereas breaks in the epithelium
would likely allow HIV to reach the lamina propria and be
captured by interstitial DCs. These and other studies show
that DCs express an array of molecules that can interact
with different pathogens (18). Depending on the DC sub-
set studied, these interactions sometimes result in DC in-
fection and other times result in a DC that carries with it an
infectious agent that can, at some later point, be transmitted
to a susceptible cell. This variability makes studies like Hu
et al. that utilize primary human tissues, with their associ-
ated resident DCs (1), even more important.
 
Prospects for Therapy.
 
Will entry inhibitors or agents that
directly and specifically target HIV prevent HIV trans-
mission? The study by Hu et al. (1) as well as the work of
others (3–6, 15, 18) certainly suggests that this general ap-
proach should be carefully examined. With an array of
entry inhibitors moving through clinical development, in-
cluding CCR5 inhibitors, CXCR4 inhibitors, fusion in-
hibitors, and compounds that prevent CD4 binding (8),
options for microbicide formulations based on knowledge
of how HIV infects cells will expand in the coming years.
Targeting cell surface receptors has some advantages, spe-
cifically the lack of variability in receptor structure and dis-
tribution between individuals compared with the impres-
sive variability of the viral Env protein. However, it is
likely that several different inhibitors will have to be em-
ployed in order to close all of the doors through which
HIV can enter.
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